Accord BioPharma Improves Patient Access with IMULDOSA®
Accord BioPharma is excited to share that its innovative drug, IMULDOSA® (ustekinumab-srlf), has been added to the formularies of Express Scripts, one of the largest pharmacy benefit managers in the nation. This pivotal development represents a significant step forward in enhancing patient access to essential therapies.
IMULDOSA®: A Breakthrough in Immunology
IMULDOSA is a biosimilar to STELARA® (ustekinumab), successfully receiving FDA approval for the treatment of numerous immune-mediated inflammatory diseases, including plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. This approval signifies that IMULDOSA is effective and has no clinically meaningful differences when compared to its reference product.
The launch of IMULDOSA in convenient pre-filled syringes and a single-dose vial for intravenous infusion emphasizes Accord BioPharma’s commitment to patient comfort and accessibility. By choosing IMULDOSA, patients gain access to a proven biologic therapy designed to enhance their quality of life.
How This Formulary Addition Benefits Patients
The inclusion of IMULDOSA in Express Scripts’ formularies ensures that more patients can access this effective therapy. Accord BioPharma understands that cost can often be a barrier to receiving necessary medical treatments. The expansion onto these formularies aligns with the company’s mission to provide affordable care solutions.
Chrys Kokino, President of Accord North America, emphasized the importance of this milestone: "At Accord BioPharma, we believe that cost shouldn't be a barrier to accessing potentially life-changing therapies. Placement on Express Scripts' formularies furthers our commitment to expanding patient access to biologic therapies."
Future Directions for Accord BioPharma
Looking ahead, Accord BioPharma is determined to continue collaborating with additional pharmacy benefit managers. This collaborative effort aims to expand nationwide access to IMULDOSA, improving healthcare outcomes for patients dealing with various inflammatory conditions.
Paul Purdy, Vice President of Market Access at Accord BioPharma, remarked, "Securing formulary coverage with Express Scripts validates our commitment to providing greater access to biologic therapies for patients managing several immune-mediated inflammatory conditions." This recognition not only signifies success for Accord BioPharma but also enhances the lives of many who will benefit from this treatment.
About Accord BioPharma
Accord BioPharma, Inc., is the U.S. specialty division of Intas Pharmaceuticals, Ltd., dedicated to providing accessible and patient-centric therapies across oncology, immunology, and critical care fields. By focusing on a patient-first approach, the company aims to develop high-quality therapies that genuinely impact patient lives.
Accord BioPharma also recognizes the vital role that biosimilars play in increasing healthcare accessibility and offering financial relief within the U.S. healthcare system. They are actively working towards building one of the most comprehensive biosimilar portfolios in the market.
Frequently Asked Questions
What is IMULDOSA®?
IMULDOSA is a biosimilar to STELARA® (ustekinumab) used for treating various immune-mediated inflammatory diseases.
Who can benefit from IMULDOSA®?
Patients suffering from plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis may benefit from IMULDOSA.
How does the inclusion in Express Scripts’ formularies benefit patients?
This inclusion increases accessibility and affordability for patients needing biologic therapies, ensuring more can receive effective treatment.
What does Accord BioPharma's mission entail?
Accord BioPharma's mission focuses on making healthcare more affordable and accessible, particularly through the development of biosimilars.
How can patients learn more about the safety of IMULDOSA®?
For comprehensive safety information, interested patients should consult the prescribing information provided by Accord BioPharma.
